Health Care & Life Sciences » Biotechnology | biOasis Technologies Inc.

biOasis Technologies Inc. | Balance Sheet

Fiscal year is March-February. All values CAD Thousands.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
1,842.20
1,638.90
1,622.70
554.30
678.00
1,360
Total Accounts Receivable
136.50
14.50
30.30
58.00
33.70
9.70
Other Current Assets
67.80
77.00
69.80
119.10
81.70
12.60
Total Current Assets
2,046.60
1,730.40
1,722.90
731.30
793.40
1,382.30
Net Property, Plant & Equipment
8.80
7.10
4.90
3.40
41.90
33.10
Intangible Assets
523.20
474.20
425.20
376.20
386.60
327.80
Total Assets
2,578.60
2,211.70
2,153.00
1,110.90
1,221.80
1,743.20
Accounts Payable
185.20
-
321.30
556.70
787.70
Other Current Liabilities
1.20
206.50
112.50
190.80
-
Total Current Liabilities
186.40
206.50
433.70
747.50
787.70
Other Liabilities
1.20
-
-
-
-
Total Liabilities
187.70
206.50
433.70
747.50
787.70
Common Equity (Total)
2,390.90
2,005.20
1,719.20
363.40
434.10
Total Shareholders' Equity
2,390.90
2,005.20
1,719.20
363.40
434.10
Total Equity
2,390.90
2,005.20
1,719.20
363.40
434.10
Liabilities & Shareholders' Equity
2,578.60
2,211.70
2,153.00
1,110.90
1,221.80

About biOasis Technologies

View Profile
Address
14 Water Street
Guilford Connecticut 06437
United States
Employees -
Website http://www.bioasis.ca
Updated 07/08/2019
biOasis Technologies, Inc. is a biopharmaceutical company focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include Transcend program as its proprietary carrier, p97, and components thereof, to deliver therapeutics and imaging agents across the blood brain barrier. The company was founded by Rob Hutchison on May 3, 2007 and is headquartered in Vancouver, Canada.